All In Biotech

Free tool

FAERS Monitor: Evoxac

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 221183 or its brand name (Evoxac, Cevimeline Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,986

Serious

1,035

52% of reports

Hospitalization

476

Death reported

69

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective150
  • headache132
  • diarrhoea123
  • nausea122
  • fatigue112
  • dyspnoea107
  • pain98
  • arthralgia97
  • off label use78
  • fall77
  • dry mouth75
  • dizziness66
  • malaise66
  • vomiting66
  • weight decreased66

Reports by year received

View as table
YearReports
200430
200529
200630
200739
200837
200948
201067
201168
201292
2013109
201487
2015139
2016170
2017112
2018107
2019105
202090
202165
202287
202384
2024138
2025127
2026126

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,173 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
dry mouthSignal759.87.8585
weight decreasedSignal662.52.059
arthralgiaSignal972.52.085
fallSignal772.52.066
headacheSignal1322.21.991
diarrhoeaSignal1232.01.764
dyspnoeaSignal1072.01.754
pain981.71.428
nausea1221.61.430
malaise661.61.314
fatigue1121.51.320
vomiting661.51.210
dizziness661.41.17
drug ineffective1501.21.05
off label use780.90.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.